Comparison efficacy of ESWT and Wharton’s jelly mesenchymal stem cell in early osteoarthritis of rat knee

Jai-Hong Cheng¹, Ching-Jen Wang¹,², Wen-Yi Chou², Shan-Ling Hsu¹,², Jen-Hung Chen², Tsai-Chin Hsu¹,²

¹Center for Shockwave Medicine and Tissue Engineering, ²Department of Orthopedic Surgery, ³Medical Research, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Received January 3, 2018; Accepted October 21, 2018; Epub February 15, 2019; Published February 28, 2019

Abstract: Application of extracorporeal shockwave therapy (ESWT) to the subchondral bone of medial tibia condyle has shown chondroprotective effects of the knee with decreased cartilage degradation and improved subchondral bone remodeling in the osteoarthritis (OA) of rat knee. Recently, transplantation of ex vivo preparations of mesenchymal stem cells (MSCs) to animal or human joints with OA seems to induce therapeutically effective repair because of paracrine responses from host cells including progenitor cells residing within the synovium. This study compared ESWT, Wharton’s jelly mesenchymal stem cells (WJMSCs) and combination of ESWT and WJMSCs therapies for early OA of the rat knee. The results showed ESWT, WJMSCs and combination of therapies significantly improved early OA knee based on analysis of pathological findings, micro-CT and immunohistochemistry (IHC) stain. The combined therapy group increased the bone volume (61.755 ± 1.537), and trabecular thickness (0.215 ± 0.014; P < 0.01) as well as reduced synovitis (1.8 ± 0.37) more than ESWT or WJMSCs individually. However, there were no significant difference in combined ESWT and WJMSCs as shown in the expressions of IGF-1 and TGF-β1 and reduction of the TUNEL activity on OA knee. Furthermore, WJMSCs treatment significantly increased the expression of the type II collagen (22.62 ± 0.84; P < 0.001) when compared with ESWT (6.97 ± 0.54) and ESWT combined with WJMSCs (8.87 ± 0.31) in OA knee. In mechanistic factors analysis, the synergistic effect was observed by ESWT combined with WJMSCs in the expression of RUNX-2, SOX-9 and Collagen Xα1 on OA knee. Our results provided the innovative information of ESWT, and WJMSCs in the treatment of early osteoarthritis of the knee in rats.

Keywords: Shockwave therapy, osteoarthritis, Wharton’s jelly mesenchymal stem cell, articular cartilage, subchondral bone

Introduction

Osteoarthritis (OA) of the knee is a degenerative joint disorder manifested with pain, deformity and functional disability due to damage of the articular cartilage. Conservative treatment is recommended in symptomatic early stage osteoarthritis of the knee, and surgery including knee replacement for late stage disease or failure to conservative treatments. Currently available methods of conservative treatment include administration of non-steroidal anti-inflammatory drugs (NSAID), weight reduction, modification of activity levels for daily living, physical therapy, knee brace support, intra-articular injections of cortisone, hyaluronic acid and platelet rich plasma (PRP) etc. Some gained limited success, but none showed universal results. Recent studies demonstrate that ESWT has chondroprotective effect on early OA changes of the knee and induces regression or retardation of OA changes in the knee on animal model [1, 2]. ESWT showed a dose-related effect on different targets such as skin flap [3, 4], tendon [5, 6], tenocyte [7], plantar fasciitis [8], bone [9], osteoarthritis of the knee [10], hip necrosis [11] and cells [12]. ESWT is characterized as noninvasive with mostly painless, effective, convenient and safe procedure without the need of surgery or surgical risks. ESWT has the potential of replacing surgery in various musculoskeletal disorders. The complication rates are low and negligible. The mechanism of shockwave therapy on tissue regeneration remains unclear. It has been reported that ESWT improves tissue regeneration by anti-inflammation, neovascularization, bone remodeling and wound healing.
ESWT verus Wharton’s jelly mesenchymal stem cells in OA knee

[13-17]. ESWT also showed the biological effects to induce specific growth factors, such as eNOS, PCNA, VEGF, BMP-2, and osteocalcin expressions during bone healing [2, 14, 18]. Extracorporeal shockwave technology has the great potential for translational medical research and development in new therapeutic methods.

Mesenchymal stem cells (MSCs) are progenitor cells of connective tissue cells, and can be isolated from many well-differentiating organs and other human sources including bone marrow, adipose tissue, skeletal muscle, umbilical cord blood and Wharton’s jelly (WJ) [19-21]. MSCs are demonstrated capability of differentiating to osteogenic, adipogenic, and chondrogenic lineages in vitro and in vivo [22, 23]. MSCs can differentiate into wide range of specialized cells of mesodermal origin such as bone cells, cartilage, fat, cardiomyocytes, muscle fibers, renal tubular cells, and break germ layer commitment as well as differentiate into cells of ectodermal origin [24]. MSCs treatment can be executed by direct replacement of injured tissue cells through paracrine effect on surrounding microenvironment, indirectly supporting revascularisation, anti-apoptosis, and modulating inflammatory response [25]. In addition, MSCs have become known as a capable tool for clinical and commercial applications of cell transplantation and cell therapy. Recently, researchers used intra-articular injection of mesenchymal stem cells (MSCs) for the repair of OA joint surface lesions through paracrine effects of MSCs [26-30]. The majority of the successful preclinical studies involved the use of autologous, culture-expanded bone marrow-derived mesenchymal stem cells (BMMSCs) or adipose-derived mesenchymal stem cells (ADMSCs) [27].

ESWT had demonstrated increased expressions of SDF-1, TGF-β and VEGF in injury tissue and these proteins induce MSCs or circulating endothelial progenitor cells (EPCs) to promote the healing of the damaged tissue to regeneration or reconstruction [31]. Equine adipose tissue-derived MSCs are improved in cell differentiation and cell proliferation by ESWT and enhances the expression of Cx43 as well as activated almost 2 fold of Erk1/2 in vitro [32]. In the current study, the results showed the efficacy of ESWT, WMSCs and combined ESWT and WJMScs on early OA knee.

Methods

Animals

The animals were treated humanely according to the guidelines from the Care and Use of Laboratory Animals, published by the National Institute of Health. All animals were housed under standard conditions at 23 ± 1°C with a 12 hours light and dark cycle. The Center for Laboratory Animals at Chang Gung Memorial Hospital (CGMH) provided veterinary care to the animals. The study was subjected to the approval of the Institutional Animal Care and Use Committee (IACUC) guidelines for the use of animals by rules of 4 R’s (replacement, reduction, refinement and rehabilitation) at CGMH.

OA knee of rat model by anterior cruciate ligament transection and medial meniscectomy

The left knee was prepared for OA knee model by anterior cruciate ligament transection (ACLT) and medial meniscectomy (MM) [10, 18]. After surgery, prophylactic antibiotic with ampicillin 25 mg/Kg was given for 3 days and a veterinarian cared for the animals. The wounds and the activities of the animals were observed daily before and after ESWT treatment until sacrifice.

ESWT application

The device of DUOLITH® SD1 ultra (Storz medical) was used to generate the focused shockwave. The shockwave was applied on the subchondral bone of the medial tibia of the left knee [1]. Each knee was treated with 800 impulses of shockwave at 0.25 mJ/mm² energy flux density in a single dose. After ESWT, the animals were returned to the cage for observation.

Isolation of human Wharton’s jelly (WJ)-derived mesenchymal stem cells and cell phenotyping

The umbilical cord was collected and stored in a sterile specimen cup containing 0.9% normal saline at 4°C until processing after delivery. The umbilical cord was washed with sterile HBSS Solution (Gibco, USA) and cut into 2 to 3 cm long pieces using a sterile blade and the vessels of the umbilical artery, vein, and outlining membrane were dissociated from the umbilical cord on Dulbecco’s Modified Eagle Me-
ESWT verus Wharton’s jelly mesenchymal stem cells in OA knee

**Experimental design**

<table>
<thead>
<tr>
<th>Group</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sham</td>
</tr>
<tr>
<td>2</td>
<td>OA</td>
</tr>
<tr>
<td>3</td>
<td>OA + 1x10⁶ cells of Wharton’s jelly mesenchymal stem cells (WJMSCs)</td>
</tr>
<tr>
<td>4</td>
<td>OA + ESWT (0.25 mJ/mm²; 800 impulses)</td>
</tr>
<tr>
<td>5</td>
<td>OA + ESWT + inject 1x10⁶ cells of WJMSCs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week</th>
<th>ACLT and medial meniscectomy</th>
<th>WJMSCs injection</th>
<th>ESWT</th>
<th>Sacrifice</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Post-treatment at 12 weeks

Sprague-Dawley rat N=6

**Figure 1.** The study design. Graphic scheme depicted the study design of the experiment including knee surgery, shockwave application, WJMSCs injection, and sacrifice of animals. The six rats were used in the experiments.

**Study design**

In this experiment, thirty Sprague-Dawley rats were used. The animals were randomized into five groups: Sham group was the baseline control and receive sham surgery of the left knee without anterior cruciate ligament transection (ACLT) and medial meniscectomy (MM) or shockwave. OA group received ACLT+MM of left knee, but no ESWT, and was used as OA changes of the knee. OA+ESWT group received ACLT+MM of the left knee, and 800 impulses of ESWT at 0.25 mJ/mm². OA+WJMSCs group received ACLT+MM, and intra-articular injection of 1 x 10⁶ WJMSCs which were suspended in 50 μL of 1 x PBS and its location was confirmed by an ultrasound Doppler scan [33, 34]. OA+ESWT+WJMSCs group received ACLT+MM of the left knee, and intra-articular injection of 1 x 10⁶ WJMSCs that were suspended in 100 μL of 1 x PBS and then after 30 min to apply 800 impulses of ESWT at 0.25 mJ/mm². All animals were scarified at 12 weeks post-treatment. The evaluations included pathological and histopathological changes of the knee and micro-CT scan. The experiment design and flow chat were showed in Figure 1.

**Micro-CT scan**

The harvested left knee was subjected to micro-CT scan (SkyScan, 1076, Kartuizersweg 3B 2550 Kontich, Belgium) analysis. The left knee was prepared and sized to fit the micro-CT for scanning. Examination of the trabecular bone included percentage trabecular bone volume fraction (BV/TV), and trabecular thickness were performed.

**Histopathological examination**

The articular cartilage and subchondral bone specimens were subjected to histopathological examination. The harvested specimens were fixed in 4% PBS-buffered formaldehyde at 37°C for 7 days, decalcified in 10% PBS-buffered EDTA at 37°C for 30 days. Decalcified specimens were fixed and subjected to paraffin wax embedding and dissection into 5 μm-thick sections. The specimens were stained with safranin-O stains. The degenerative changes of the articular cartilage were graded histologically using OARSI score.

**Synovitis scoring**

The tissue was stained with haematoxylin and eosin to evaluate synovitis score including thickening of the synovial lining, cellular hyperplasia and infiltration into joint cavity and synovi-
ESWT versus Wharton’s jelly mesenchymal stem cells in OA knee

imm. Three features of chronic synovitis were described the scores ranks were defined as follow (1) 0 to 1 = no synovitis; (2) 2 to 4 = low-grade synovitis; (3) 5 to 9 = high-grade synovitis [35].

Immunohistochemical analysis

The articular cartilage and subchondral bone specimens were analyzed with immunohistochemical analysis by anti-human specific nuclei antigen antibody, anti-rat TGF-β1 (transforming growth factor β1), anti-rat IGF-1 (Insulin-like growth factor 1), anti-rat type II collagen, TUNEL activity, MMP-13, RUNX-2, SOX-9 and Collagen Xα1. The harvested specimens were fixed in 4% PBS-buffered formaldehyde for 48 hours and decalcified in PBS-buffered 10% EDTA solution. Decalcified tissues were embedded in paraffin wax. The specimens were cut longitudinally into 5 μm thick sections and transferred to polylysine-coated slides. Sections of the specimens were immunostained with specific reagents for anti-human specific nuclei antigen antibody, anti-rat TGF-β1, IGF-1 and type II collagen (Santa Cruz Biotechnology Inc, CA, USA), MMP-13, RUNX-2, SOX-9 (Abcam, Cambridge, UK), and Collagen Xα1 (Gene Tex, Inc., USA) to identify the location of WJMSCs, cartilage, and osteogenesis markers in bone remodeling and cartilage regeneration of rats. The immuno-reactivity in specimens were demonstrated using a horseradish peroxidase (HRP)-3’, 3’-diaminobenzidine (DAB) cell and tissue staining kit (R & D Systems, Inc. Minneapolis, MN, USA). In Situ Cell Death Detection Kits (Roche Diagnostic, Mannheim, Germany) accomplished the TUNEL analysis following a manufacture instruction. TUNEL color stains were performed by using NBC/BCIP substrate (Sigma-Aldrich, St. Louis, MO, USA). The immuno-activities were quantified from five areas in three sections of the same specimen using a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Gottingen, Germany). All the images of each specimen were captured using a Cool CCD camera (SNAP-Pro c.f. Digital kit; Media Cybernetics, Silver Spring, MD, USA). Images were analyzed using an Image-Pro® Plus image-analysis software (Media Cybernetics, Silver Spring, MD, USA). The percentage of each area was counted by immuno-labeled positive cells over the total cells as the results.

Statistical analysis

SPSS ver. 17.0 (SPSS Inc., USA) was used in statistical analysis. Calculated data was expressed as mean ± SD and One-way ANOVA with Tukey tests for post hoc (normal distribution) were used for group comparisons. Ranking data (non-normal distribution) was used Kruskal-Wallis test for comparisons of multiple groups. A statistical significance was set at P < 0.05, P < 0.01 and P < 0.001.

Results

Characterization of WJMSCs

WJMSCs used in this experiment showed fibroblast-like morphology (Figure 2). Flow cytometric analysis demonstrated that the WJMSCs contained positive expressions of CD44 (98.65%), CD105 (88.86%), and CD166 (85.90%), and negative expressions of CD14 (18.93%), and CD133 (1.87%) (Figure 2).

ESWT, WJMSCs and ESWT combined with WJMSCs significantly improved the damage of articular cartilage in early OA knee

ESWT, WJMSCs and ESWT combined with WJMSCs showed protection of the damaged articular cartilage in early treatment of OA rat knee. We also observed the changes of articular cartilage of osteoarthritis with OARSI score by safranin O stain in sham (0 ± 0; P < 0.001), OA+ESWT (6.6 ± 0.33; P < 0.001), OA+WJMSCs (4.9 ± 0.83; P < 0.001) and OA+ESWT+WJMSCs (6.0 ± 0.32; P < 0.001) by compared with OA (13.2
The levels of protective effect on articular cartilage were not significant difference among ESWT, WJMSCs and ESWT+WJMSCs on OA knee. In the experiment, we surveyed the WJMSCs by using anti-human specific nuclei antigen antibody for IHC stain, but there were no signal detected at 12 week post-treatment.
ESWT versus Wharton’s jelly mesenchymal stem cells in OA knee

The results of micro-CT scan were summarized in Figure 5. The bone volume (BV/TV) and trabecular thickness decreased in the proximal tibia in OA (55.208 ± 0.999 and 0.162 ± 0.004) as compared with Sham (62.383 ± 0.692; \( P < 0.001 \) and 0.173 ± 0.004; \( P = 0.06 \)). ESWT, WJMSCs and ESWT combined with WJMSCs significantly improved the bone volume in OA+.
ESWT versus Wharton’s jelly mesenchymal stem cells in OA knee

ESWT (59.767 ± 0.88; P < 0.01), OA+WJMSCs (60.155 ± 1.049; P < 0.01) and OA+ESWT+WJMSCs (61.755 ± 1.537; P < 0.01) compared with OA (55.208 ± 0.999). In trabecular thickness, the results showed more effective in the improvement of subchondral plate thickness in OA+WJMSCs (0.196 ± 0.005; P < 0.05) and OA+ESWT+WJMSCs (0.215 ± 0.014; P < 0.05) than OA+ESWT (0.175 ± 0.002). Finally, ESWT combined with WJMSCs had a synergistic effect for bone regeneration in the treatment of early OA knee.

ESWT combined with WJMSCs significantly improved synovitis of OA knee

Synovitis of synovial membrane was measured after treatment (Figure 6). The mononuclear cells and neutrophils were infiltrated to the synovial membrane in OA knee. Lining cell layers were observed in composed large cells to form the irregular layered tissue (Figure 6A). ESWT (2.6 ± 0.40; P < 0.05), WJMSCs (2.4 ± 0.24; P < 0.05) and ESWT combined with WJMSCs (1.8 ± 0.37; P < 0.01) were significant improved the synovitis by comparing with OA (4.2 ± 0.58) (Figure 6B). Among the treatment groups, ESWT plus WJMSCs group was better than ESWT and WJMSCs alone on synovitis of OA knee, but no statistical significance was noticed among the groups.

The synergistic effect of OA+WJMSCs+ESWT in the expression of MMP-13, RUNX-2, SOX-9 and Collagen Xα1 on OA knee

The key factors in chondrogenesis were measured by immunohistochemical analysis including MMP-13, RUNX-2, SOX-9 and Collagen Xα1 in the OA knee treatments (Figure 8). The expression of MMP-13 was significantly reduced in OA+ESWT, OA+WJMSCs and OA+ESWT+WJMSCs groups compared with OA group (P < 0.001). Further, the expressions of RUNX-2, SOX-9 and Collagen Xα1 were statistically increased in OA+ESWT, OA+WJMSCs and OA+ESWT+WJMSCs groups by compared with OA group. Among the treatment groups, the ESWT combined with WJMSCs has the synergistic effect in the expression of RUNX-2, SOX-9 and Collagen Xα1.

Discussion

In the current study, we found that the treatment of the rat OA knee with ESWT, WJMSCs...
Figure 7. Immunohistochemical analysis of the specific molecular factors in the treatments on OA knee. The immunohistochemical stains (left) and quantification (right) showed the expressions of the type II collagen, TUNEL activity, IGF-1 and TGF-β1 after treatments on OA knee. The type II collagen and TUNEL activity were measured in the articular cartilage as well as IGF-1 and TGF-β1 were observed in the subchondral bone of the knee. The field of view was 100 x magnification. *P < 0.05, **P < 0.01, ***P < 0.001 comparing to OA group. The ###P < 0.001 comparing to OA+WJMSCs group. All rats were n = 6.
Figure 8. The expression of the factors in the chondrogenesis after treatments on OA knee. The immunohistochemical stains (left) and quantification (right) showed the levels of the MMP-13, RUNX-2, SOX-9 and Collagen Xα1 after treatments on OA knee. The field of view was 100 × magnification. *P < 0.05, **P < 0.01, ***P < 0.001 comparing to OA group. The #P < 0.05, ##P < 0.01 and ###P < 0.001 comparing to OA+ESWT group. All rats were n = 6.
and combined therapy resulted in up-regulation of cartilage specific protein of type II collagen and growth factors including IGF-1 and TGF-β1 and reduced activity of TUNEL expression in articular cartilage and inflammation of synovial membrane.

Bone marrow-derived mesenchymal stem cells (BMMSCs) were studied and documented in the field of stem cell studies. However, BMMSCs have limitation in cell numbers and require expansion in vitro with the risk of loss of stemness properties, inducing artifactual chromosomal changes and contamination [22, 36]. ADMSCs from adipose tissue recently emerged as another resource of MSCs but it requires tissue collection to gain MSCs [37, 38]. In this study, WJMSCs singularly and combined with ESWT on OA knee were utilized. WJMSCs are extra-embryonic tissue-derived MSCs with immune privilege, broader multipotent differentiation plasticity, and faster proliferation than adult MSCs [39, 40]. Moreover, WJMSCs could be isolated and used without ethical problem, because extra-embryonic tissues are normally discarded after birth [39, 41]. WJMSCs enhance chondrogenic differentiation more than BM-MSCs in nanofibrous scaffolds and two-stage culture medium environment [42]. WJMSCs are effective in preventing OA changes of the knee, including synovitis that is a major target and modulation in matrix-degrading enzymes in animal studies [43]. There are many clinical trials to initiate and observe the delivery of MSCs by an intra-articular injection into the knee but, no optimal dose and vehicle are reported [26]. The process of treatment for OA knee are complicated factors, and the long-term results of MSCs for the treatment of OA knee are not completely available [44-46].

ESWT has been shown effectiveness on OA disease associated with many growth factors and cytokines for tissue repair [47, 48]. However, the time for tissues repair after ESWT is still unknown. In addition, shortening the time interval to achieve tissue regeneration after ESWT is uncertain. In the study, combination of ESWT and WJMSCs with is the best approach in OA knee. Prior studies reported that ESWT and MSCs can induce expressions of growth factors and cytokines to promote cell proliferation and osteogenesis [26, 48, 49]. However, the synergistic effects of the combined therapy remain unclear and further investigations are needed. In the current study, we had shown that ESWT, WJMSCs and combined therapy improved the OA knee in a rat model. In addition, the synergistic effects of ESWT and WJMSCs in the improvement of bone volume and trabecular thickness (Figure 5) as well as in the expressions of RUNX-2, SOX-9 and Collagen Xα1 which were important factors in the chondrogenesis (Figure 8). However, no significant difference was found in articular cartilage repair, synovitis score and the expression of growth factors, such as IGF-1 and TGF-β1 (Figures 4, 6 and 7). No synergistic effects of combined therapy might be due to the expression levels of cytokines and growth factors or other unknown factors. Additional experiments are needed to elucidate the phenomenon. In OA knee, WJMSCs significantly improved the expression of type II collagen more than OA+ESWT or OA+ESWT+WJMSCs groups (Figure 7). The expression of type II collagen of WJMSCs might be modulated by ESWT in combined therapy on OA knee.

The study has several limitations as followings. The results of the study are obtained from small animals that may differ from the larger animal model or human clinical trial. Furthermore, the dose of shockwave were based on previous animal studies and reference for cell-based therapies [1, 33, 34]. These may not be optimal dose for human clinical trial. The expression of growth factors and cytokines after ESWT and WJMSCs in small animals may not be as accurate as human projects.

In conclusion, combined ESWT and WJMSCs is more effective in early knee OA in rats. These finding elucidated the insights for innovation strategy for combined ESWT with WJMSCs in the treatment of OA knees.

Acknowledgements

We are grateful to the Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital for the supporting of this project. The funding sources are from Chang Gung Medical Foundation (CMRPG8E1231 and CLRPG8E-0131).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ching-Jen Wang, Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, 123 Tai-Pei Road, Niao Sung District, Kaohsiung 833, Taiwan. Tel: 886-7-
ESWT verus Wharton’s jelly mesenchymal stem cells in OA knee

References


ESWT verus Wharton’s jelly mesenchymal stem cells in OA knee


ESWT verus Wharton’s jelly mesenchymal stem cells in OA knee

